Dergiler / Eurasian Journal of Critical Care / 2021 / Cilt: 3 - Sayı: 3

A fatal side effect of piperacillin/tazobactam use: a case report.

Sayfa
119–121
Yayın Tarihi
2021-12-28
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Drug-induced QT prolongation with T wave inversion is a complex regulatory and clinical problem due to the rarity of this potentially fatal adverse incident.
📊
Temel Bulgular & Veri:A 68-year-old female patient was receiving piperacillin/tazobactam therapy for a complicated urinary tract infection.
💡
Sonuç & Katkı:We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:torsades de pointes · drug-induced long QT syndrome · piperacillin/tazobactam

Abstract

Drug-induced QT prolongation with T wave inversion is a complex regulatory and clinical problem due to the rarity of this potentially fatal adverse incident. A 68-year-old female patient was receiving piperacillin/tazobactam therapy for a complicated urinary tract infection. She has had normal ECG findings before the antibacterial therapy. After the treatment, the patient worsens due to long QT which is predisposed to torsades de pointes. As a result of the researches, it was understood that the cause of long QT was piperacillin/tazobactam. We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.

🔖

Bu Makaleye Atıf Yap

DUYAN, M., GÜNLÜ, S., SARIDAŞ, A., CANDER, B., SOLAÇ, Y. (2021). A fatal side effect of piperacillin/tazobactam use: a case report.. Eurasian Journal of Critical Care, Cilt: 3 - Sayı: 3, 119–121. https://ajindex.com/articles/756069

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. :1. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006
  2. 17(3):333-336. doi:10.1111/j.1540-8167.2006.00408.x 2. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002
  3. 17(1):43-51. doi:10.1097/00001573-200201000-00007 3. Woosley RL. QT Drug Lists by Risk Groups. AZ: Arizona Center for Research and Education on Therapeutics. Published 2009. Accessed September 1, 2021. http:// www.azcert.org/medical-pros/drug-lists/drug-lists.cfm 4. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006
  4. 316(3):1098-1106. doi:10.1124/jpet.105.093393 5. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010
  5. 33(4):303-314. doi:10.2165/11531850-000000000-00000 6. Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsade de pointes in a hospitalised surgical patient. Sultan Qaboos Univ Med J. 2013
  6. 13(1):152-155. doi:10.12816/0003211 7. Piperacillin and tazobactam: Drug information. Published December 6, 2020. Accessed semtember 1, 2021. https://www.uptodate.com/contents/piperacillin-and-tazobactam-drug-information search=piperacillin%20tazobactam&source=panel_search_result&selectedTitle=1~104&usage_type=panel&kp_tab=drug_general&display_rank=1#F210382